AstraZeneca and Daiichi Sankyo Collaborate with Summit Therapeutics to Evaluate Combination Therapy
Daiichi Sankyo (DSKYF) and AstraZeneca have partnered with Summit Therapeutics (SMMT) in a clinical trial collaboration aimed at evaluating the combination of Datroway (datopotamab deruxtecan) and ivonescimab across various tumor types. The companies announced this partnership on Friday, highlighting their shared commitment to advancing cancer treatment through innovative therapeutic combinations. Datroway is an antibody-drug conjugate developed by AstraZeneca for the targeted delivery of chemotherapy in certain cancers. Ivonescimab, from Summit Therapeutics, is a bispecific monoclonal antibody designed to enhance immune response against tumors. The collaboration aims to assess whether combining these two therapies can improve treatment outcomes. This partnership reflects ongoing efforts within the biopharmaceutical industry to explore synergistic drug combinations for oncology applications.
Topics: clinical trial collaboration Datroway (datopotamab deruxtecan) ivonescimab